ft 25 jun 93 technolog top hormon market menopaus treatment lucr say clive cookson seri drug discoveri 51 year old product extract pregnant mare urin turn unexpectedli pharmaceut blockbust success premarin worldwid sale 20 per cent dollar 642m pound 428m last year project reach dollar 1bn 1995 testimoni fast grow popular hormon replac therapi women menopaus although hrt go long averag menopaus woman new research find propel growth show oestrogen premarin reliev immedi symptom menopaus hot flush night sweat fatigu vagin dryness also help prevent two seriou health problem old age osteoporosi fragil bone heart diseas time drug compani develop conveni way deliv hrt tradit premarin tablet sold wyeth pharmaceut subsidiari american home product import innov transderm patch pioneer ciba switzerland releas hormon slowli blood skin menopaus defin narrowli woman last menstrual period occur averag age 51 term use loos describ chang trigger ovari declin capac produc oestrogen femal sex hormon typic start late 40 continu well 50 fall oestrogen level affect normal function mani bodi system includ skin bone blood vessel sex organ import long term impact acceler normal age relat loss bone densiti miner result osteoporosi caus 1 3m bone fractur year us total cost health care estim dollar 10bn year half women break hip old age never abl walk without assist one five die within year fractur menopaus also remov protect heart diseas given oestrogen reduc clog arteri simul healthi growth blood vessel although younger women much less like men age die heart attack stroke death increas rapidli age 50 hrt aim restor oestrogen blood level slightli normal menopaus although wyeth ciba domin market 20 hrt product current avail includ surgic implant cream pessari well tablet skin patch contain natur oestrogen either human oestradiol conjug oestrogen pregnant mare much less potent synthet hormon incorpor oral contracept pill addit oestrogen women hrt whose womb remov hysterectomi advis take cyclic dose second hormon progestogen role prevent excess cell build line uteru condit eventu lead cancer womb clinic evid long term benefit hrt build steadili world menopaus congress stockholm hear week risk hip fractur reduc least half five year treatment risk heart attack may cut 45 per cent proport menopaus women uk hrt increas 4 per cent 9 per cent past five year accord amar trust medic chariti specialis hrt us 15 per cent hrt howev scope far women benefit hrt say val godfre deputi medic director amar trust busi famili doctor time explain hrt 10 15 minut allot typic consult say work best therapi individu result mani women give two three week side effect therapi chanc much good side effect caus oestrogen progestogen combin includ breast tender bloat leg cramp normal disappear within three month bodi becom accustom rais hormon level may also possibl reduc side effect switch differ combin tablet skin patch beyond immedi side effect women steer clear hrt afraid long term risk hormon consumpt think wrong interfer artifici natur age process view author germain greer expound anti hrt book chang publish 1991 book menopaus lucr publish genr gail sheehi silent passag favour hrt head us bestsel list last year potenti seriou long term risk hrt small increas chanc develop breast cancer still medic controversi godfre conced risk breast cancer may increas 1 12 1 9 15 year hrt women like take sex hormon still want protect osteoporosi may prescrib bone strengthen drug notabl calcitonin give calcium main miner bone directli dietari supplement appear prevent osteoporosi well nourish women calcitonin hormon regul calcium phosphat level bodi help reduc resorpt miner bone blood sandoz switzerland lead dollar 1bn year calcitonin market miacalc synthet version salmon calcitonin recent calcitonin inject miacalc avail conveni nasal spray bisphosphon potent inhibitor bone resorpt new categori drug treat osteoporosi sale still small dollar 80m last year accord arvind desai analyst mehta isali new york healthcar invest compani expect rise new product come clinic trial meanwhil new gener transderm patch fuell growth hrt market first evorel launch europ earli year ortho cilag subsidiari johnson amp johnson ciba origin estraderm patch appli twice week buttock top leg thick 0 1 mm evorel thinner estraderm contain oestrogen dispers matrix rather liquid reservoir ortho cilag quot clinic studi show evorel suffer less two problem first gener patch tendenc fall irrit skin compani develop second gener hrt patch includ two us drug deliveri compani noven cignu ethic hold uk noven sign licenc agreement rhone poulenc rorer europ ciba us cignu collabor warner lambert main advantag patch tablet apart conveni hormon diffus straight bloodstream patch avoid give larg dose oestrogen liver say john stevenson consult endocrinologist wynn institut metabol research therefor less like caus metabol disturb might seen oral rout menopaus relat drug one fastest grow pharmaceut sector desai point iron growth base less new chemic well known natur hormon desai expect overal market menopaus osteoporosi bone diseas treatment continu grow 15 20 per cent year least 1996 rate expans could even faster suffici breadth new product avail seri continu next month articl arthriti treatment market project menopaus osteoporosi bone diseas therapi compani product sale dollar million oestrogen 1991 1992 1993 1994 1995 1996 american home product premarin 540 642 760 875 960 1 010 ciba estraderm comb 225 300 390 467 520 550 johnson amp johnson evorel 20 45 65 115 ciba new patch 50 100 160 rhone poulenc 35 80 rorer new patch american home product premarin mpa 45 125 sanofi warner lambert new patch 40 80 other variou 275 298 315 333 365 415 oestrogen subtot 1 040 1 240 1 485 1 770 2 130 2 535 calcitonin subtot 1 033 1 194 1 320 1 415 1 510 1 585 bisphosphon subtot 50 80 100 195 365 700 drug subtot 155 170 205 230 255 275 grand total 2 278 2 684 3 110 3 610 4 260 5 095 sourc mehta isali